Skip to main content
Premium Trial:

Request an Annual Quote

Fingerprints Short Reads: Jan 1, 2004

Premium

Friedrich von Bohlen announces his decision to step down as CEO of Lion Biosciences, not long after the company said it expected to lay off 30 percent of its staff by March 31. Von Bohlen says his departure will help the company in its realignment to a stronger IT focus.

 

Richard Michelmore is the founding director of the University of California, Davis, Genome Center. Michelmore, who has been at Davis for some 22 years, will be in charge of hiring 15 new bioinformatics and genomics faculty members.

 

Steve Lincoln joins Affymetrix as vice president of informatics. Lincoln previously held jobs as bioinformatics VP at Incyte and CSO for InforMax.

 

Deborah Neff, formerly worldwide president at BD Biosciences, joins biomarker pattern detection company Biospect as its president and CEO.

 

Invitrogen hires Joseph Rodriguez as senior veep of human resources. Rodriguez has gained experience at such places as Home Depot, PepsiCo, and Allied Signal.

 

Last seen as chief medical officer of NimbleGen, David Cooper takes on the role of president and CMO at Direct Wireless, a Texas company which recently shed its telecom identity and acquired Barnhill Genomics as it entered the discovery and diagnostic realms.

Peter Loescher is promoted to COO of Amersham and continues to lead Amersham Health. Before joining Amersham in late 2002, Loescher was CEO of Aventis Pharma in Japan.

 

LabCorp finds a VP/national director of genetics and genomics in Paul Billings, who previously worked as vice president for life sciences and clinical affairs for Wipro HealthSciences.

 

Qiagen plays the shuffling game: cofounder Metin Colpan steps down from his CEO post and will become senior technology advisor. Meanwhile, longtime CFO Peer Schatz will replace Colpan as chief executive.

 

Sharan Pagano becomes vice president of business development and alliances at Genstruct, a Cambridge, Mass.-based firm that develops biological models and attempts to identify biomarkers. Pagano’s 19 years of experience includes time at Incyte, Proteome, and Genetics Institute.

 

Robert Middlebrook becomes the first chief corporate development officer for Perlegen Sciences after spending 11 years with Fidelity Investments.

 

Exelixis announces that CSO Geoffrey Duyk is leaving the company. Frank McCormick, a member of the board, will take on an advisory position in the R&D arm to help ease the transition.

Ivan Richards, who was with Pharmacia and then Pfizer, is the new senior director of pharmacology at Sirna Therapeutics.

 

Stephen Sharp heads to Sequenom, where he will be senior product marketing manager for bioinformatics and gene expression. Sharp was last at Iobion Informatics in his post as director of marketing.

 

Alnylam Pharmaceuticals names Barry Greene COO. Greene comes from Duke University and Millennium Pharmaceuticals.

 

Gene Logic cuts its workforce by 50 jobs in database development and production. Caliper Technologies announces its own layoffs, following the acquisition of Zymark last July, which are expected to affect 65 employees, including seven VP-level people.

 

Ardais Genomics, a clinical genomics company based in Lexington, Mass., names Donald Hawthorne as president and CEO, replacing Gregory Phelps. Hawthorne comes from a financial background, previously working at equity firm Ampersand Ventures.

 

Andre Pernet, who has worked at Abbott Laboratories and Genset, is the new president of Quark Biotech in Fremont, Calif. Pernet serves on the boards of CURx Pharma and Kaleidos Pharmaceuticals.

 

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.